Parallax Volatility Advisers
CYTK icon

Parallax Volatility Advisers’s Cytokinetics CYTK Stock Holding History

Parallax Volatility Advisers’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,100
Closed -$388K – 1551
2025
Q4 		$388K Hold
6,100
– – ﹤0.01% 1271
2025
Q3 		$335K Hold
6,100
– – ﹤0.01% 1305
2025
Q2 		$202K Hold
6,100
– – ﹤0.01% 1329
2025
Q1 		$245K Sell
6,100
-44,200
-88% -$2.03M ﹤0.01% 1301
2024
Q4 		$2.37M Buy
50,300
+44,200
+725% +$2.3M ﹤0.01% 1089
2024
Q3 		$322K Sell
6,100
-300
-5% -$16.7K ﹤0.01% 1602
2024
Q2 		$347K Buy
6,400
+300
+5% +$18.1K ﹤0.01% 1509
2024
Q1 		$428K Sell
6,100
-4,400
-42% -$340K ﹤0.01% 1448
2023
Q4 		$877K Buy
+10,500
New +$380K ﹤0.01% 1454
2023
Q1 		– Sell
-500
Closed -$22.9K – 2807
2022
Q4 		$22.9K Hold
500
– – ﹤0.01% 2469
2022
Q3 		$24K Buy
+500
New +$24.1K ﹤0.01% 2714

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Parallax Volatility Advisers's CYTK Position: Q1 2026 in Review

Parallax Volatility Advisers sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 3,039 shares — an estimated $193K sold.

Parallax Volatility Advisers first reported a position in CYTK in Q4 2017 and held it in 12 quarters. The position peaked at $2.03M in Q3 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Parallax Volatility Advisers reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Parallax Volatility Advisers sold 3,039 Cytokinetics shares in Q1 2026, an estimated $193K.
  • Parallax Volatility Advisers first reported a position in Cytokinetics in Q4 2017 and held it in 12 quarters.
  • Parallax Volatility Advisers's Cytokinetics position peaked at $2.03M in Q3 2024.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.